Hao Chen

Years Active: 2020-2022
Publications (10 Years): 5

Purdue University

Purdue University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Purdue University Aug 20 2016

United States

Graduate Student :: MCMP, College of Pharmacy

Education History

Purdue University Aug 20 2016

United States

PHD :: MCMP, College of Pharmacy

Shanghai Jiao Tong University Sep 01 2013 - Mar 15 2016

China

MSC :: School of Pharmacy

Shanghai Jiao Tong University Sep 01 2009 - Jul 01 2013

China

BSC :: School of Pharmacy

Publications

Hao Chen, Gregory M Cresswell, Sarah Libring, Mitchell G Ayers, Jinmin Miao, Zhong-Yin Zhang, Luis Solorio, Timothy L Ratliff, Michael K Wendt
Tumor Cell-Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer. Cancer research communications 2 (10) (2022)
Hao Chen, Gregory M Cresswell, Sarah Libring, Mitchell G Ayers, Jinmin Miao, Zhong-Yin Zhang, Luis Solorio, Timothy L Ratliff, Michael K Wendt
Tumor Cell-Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer. Cancer research communications 2 (10) (2022)
Aaron D Krabill, Hao Chen, Sajjad Hussain, Chad S Hewitt, Ryan D Imhoff, Christine S Muli, Chittaranjan Das, Paul J Galardy, Michael K Wendt, Daniel P Flaherty
Optimization and Anti-Cancer Properties of Fluoromethylketones as Covalent Inhibitors for Ubiquitin C-Terminal Hydrolase L1. Molecules (Basel, Switzerland) 26 (5) (2021)
Saeed S Akhand, Hao Chen, Stephen Connor Purdy, Zian Liu, Joshua C Anderson, Christopher D Willey, Michael K Wendt
Fibroblast growth factor receptor facilitates recurrence of minimal residual disease following trastuzumab emtansine therapy. NPJ breast cancer 7 (1) (2021)
Hao Chen, Sarah Libring, Kasi Viswanatharaju Ruddraraju, Jinmin Miao, Luis Solorio, Zhong-Yin Zhang, Michael K Wendt
SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer. Oncogene 39 (49) (2020)

Hao Chen.css-eqlu8i{font-size:small;padding-left:4px;}